Cellular Therapy Using Epitope-Imprinted Composite Nanoparticles to Remove α-Synuclein from an In Vitro Model

Several degenerative disorders of the central nervous system, including Parkinson’s disease (PD), are related to the pathological aggregation of proteins. Antibodies against toxic disease proteins, such as α-synuclein (SNCA), are therefore being developed as possible therapeutics. In this work, one...

Full description

Saved in:
Bibliographic Details
Published inCells (Basel, Switzerland) Vol. 11; no. 16; p. 2584
Main Authors Lee, Mei-Hwa, Jan, Jeng-Shiung, Thomas, James L, Shih, Yuan-Pin, Li, Jin-An, Lin, Chien-Yu, Ooya, Tooru, Barna, Lilla, Mészáros, Mária, Harazin, András, Porkoláb, Gergő, Veszelka, Szilvia, Deli, Maria A, Lin, Hung-Yin
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.08.2022
MDPI
Subjects
Adsorption
Alzheimer's disease
Antibodies
Antigenic determinants
Binding sites
Brain
Calorimetry
Cell therapy
Cellular therapy
Central nervous system
Communication
CRISPR
Dementia
Endothelial cells
Epitopes
gene activation
Health aspects
High-performance liquid chromatography
Light scattering
magnetic nanoparticles
Membrane proteins
Methods
Movement disorders
Nanoparticles
Neurodegenerative diseases
Parkinson's disease
peptide imprinting
Peptides
protein extraction
Proteins
Quantum dots
Synuclein
Titration
α-synuclein
Taiwan
Online AccessGet full text

Cover

More Information
Summary:Several degenerative disorders of the central nervous system, including Parkinson’s disease (PD), are related to the pathological aggregation of proteins. Antibodies against toxic disease proteins, such as α-synuclein (SNCA), are therefore being developed as possible therapeutics. In this work, one peptide (YVGSKTKEGVVHGVA) from SNCA was used as the epitope to construct magnetic molecularly imprinted composite nanoparticles (MMIPs). These composite nanoparticles were characterized by dynamic light scattering (DLS), high-performance liquid chromatography (HPLC), isothermal titration calorimetry (ITC), Brunauer–Emmett–Teller (BET) analysis, and superconducting quantum interference device (SQUID) analysis. Finally, the viability of brain endothelial cells that were treated with MMIPs was measured, and the extraction of SNCA from CRISPR/dCas9a-activated HEK293T cells from the in vitro model system was demonstrated for the therapeutic application of MMIPs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells11162584